The Erythrocyte Sedimentation Rate Is Associated with the Development of Visual Complications in Biopsy-Proven Giant Cell Arteritis

Seminars in Arthritis and Rheumatism

Volumn 38, Issue 2, 2008, Pages 116-123

  Lopez Diaz, Maria J ^a   Llorca, Javier ^b   Gonzalez Juanatey, Carlos ^c   Peña Sagredo, Jose L ^d   Martin, Javier ^e   Gonzalez Gay, Miguel A ^a  

^a Division of Rheumatology   (Spain)

^b UNIVERSITY OF CANTABRIA   (Spain)

^c HOSPITAL XERAL CALDE   (Spain)

^d HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^e CSIC   (Spain)

Author keywords

erythrocyte sedimentation rate; giant cell arteritis; predictors of permanent visual loss; visual ischemic complications

Indexed keywords

METHYLPREDNISOLONE; PREDNISONE;

ARTICLE; BLOOD VESSEL BIOPSY; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GIANT CELL ARTERITIS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VISUAL IMPAIRMENT;

ALBUMINS; ALKALINE PHOSPHATASE; BIOPSY, NEEDLE; BLINDNESS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; FEMALE; GIANT CELL ARTERITIS; GLUCOCORTICOIDS; HUMANS; ISCHEMIA; LEUKOCYTE COUNT; MALE; PLATELET COUNT;

EID: 52149123926     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2007.10.014     Document Type: Article

References (41)

1. Gonzalez-Gay M.A., and Garcia-Porrua C. Epidemiology of the vasculitides. Rheum Dis Clin North Am 27 (2001) 729-749
2. Salvarani C., Cantini F., Boiardi L., and Hunder G.G. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 347 (2002) 261-271
3. Hayreh S.S., Podhajsky P.A., and Zimmerman B. Ocular manifestations of giant cell arteritis. Am J Ophthalmol 125 (1998) 509-520
4. Levine S.M., and Hellmann D.B. Giant cell arteritis. Curr Opin Rheumatol 14 (2002) 3-10
5. Hellmann D.B. Temporal arteritis: a cough, toothache, and tongue infarction. JAMA 287 (2002) 2996-3000
6. Hunder G.G., Bloch D.A., Michel B.A., Stevens M.B., Arend W.P., Calabrese L.H., et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 33 (1990) 1122-1128
7. Salvarani C., and Hunder G.G. Giant cell arteritis with low erythrocyte sedimentation rate: frequency of occurrence in a population-based study. Arthritis Rheum 45 (2001) 140-145
8. Gonzalez-Gay M.A., Lopez-Diaz M.J., Barros S., Garcia-Porrua C., Sanchez-Andrade A., Paz-Carreira J., et al. Giant cell arteritis: laboratory tests at the time of diagnosis in a series of 240 patients. Medicine (Baltimore) 84 (2005) 277-290
9. Salvarani C., Cimino L., Macchioni P., Consonni D., Cantini F., Bajocchi G., et al. Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis. Arthritis Rheum 53 (2005) 293-297
10. Gonzalez-Gay M.A. Giant cell arteritis and polymyalgia rheumatica: two different but often overlapping conditions. Semin Arthritis Rheum 33 (2004) 289-293
11. Gonzalez-Gay M.A., Barros S., Lopez-Diaz M.J., Garcia-Porrua C., Sanchez-Andrade A., and Llorca J. Giant cell arteritis: disease patterns of clinical presentation in a series of 240 patients. Medicine (Baltimore) 84 (2005) 269-276
12. Gonzalez-Gay M.A., García-Porrua C., Guerrero J., Rodriguez-Ledo P., and Llorca J. The epidemiology of the primary systemic vasculitides in northwest Spain: implications of the Chapel Hill Consensus Conference definitions. Arthritis Rheum 49 (2003) 388-393
13. Garcia-Porrua C., and Gonzalez-Gay M.A. Comparative clinical and epidemiological study of hypersensitivity vasculitis versus Henoch-Schönlein purpura in adults. Semin Arthritis Rheum 28 (1999) 404-412
14. Lie J.T., and Members and Consultants of the American College of Rheumatology Subcommittee on classification of vasculitis. Illustrated histopathologic classification criteria for selected vasculitis syndromes. Arthritis Rheum 33 (1990) 1074-1087
15. Gonzalez-Gay M.A., Alonso M.D., Aguero J.J., Bal M., Fernandez-Camblor B., and Sanchez-Andrade A. Temporal Arteritis in a Northwestern Area of Spain: study of 57 biopsy proven patients. J Rheumatol 19 (1992) 277-280
16. Gonzalez-Gay M.A., Garcia-Porrua C., Llorca J., Hajeer A.H., Brañas F., Dababneh A., et al. Visual manifestations of giant cell arteritis. Trends and clinical spectrum in 161 patients. Medicine (Baltimore) 79 (2000) 283-292
17. Gonzalez-Gay M.A., Garcia-Porrua C., and Vazquez-Caruncho M. Polymyalgia rheumatica in biopsy proven giant cell arteritis does not constitute a different subset but differs from isolated polymyalgia rheumatica. J Rheumatol 25 (1998) 1750-1755
18. Gonzalez-Gay M.A., Garcia-Porrua C., Vazquez-Caruncho M., Dababneh A., Hajeer A., and Ollier W.E. The spectrum of polymyalgia rheumatica in Northwestern Spain: incidence and analysis of variables associated with relapse in a ten year-study. J Rheumatol 26 (1999) 1326-1332
19. Gonzalez-Gay M.A., Garcia-Porrua C., Rivas M.J., Rodriguez-Ledo P., and Llorca J. Epidemiology of biopsy proven giant cell arteritis in northwestern Spain: trend over an 18 year period. Ann Rheum Dis 60 (2001) 367-371
20. Gonzalez-Gay M.A. The diagnosis and management of patients with giant cell arteritis. J Rheumatol 32 (2005) 1186-1188
21. Gonzalez-Gay M.A., Blanco R., Abraira V., Garcia-Porrua C., Ibañez D., Garcia-Pais M.J., et al. Giant cell arteritis in Lugo, Spain, is associated with low longterm mortality. J Rheumatol 24 (1997) 2171-2176
22. Gonzalez-Gay M.A., Pineiro A., Gomez-Gigirey A., Garcia-Porrua C., Pego-Reigosa R., Dierssen-Sotos T., et al. Influence of traditional risk factors of atherosclerosis in the development of severe ischemic complications in giant cell arteritis. Medicine (Baltimore) 83 (2004) 342-347
23. Gonzalez-Gay M.A., Garcia-Porrua C., Amor-Dorado J.C., and Llorca J. Fever in biopsy-proven giant cell arteritis: clinical implications in a defined population. Arthritis Rheum 51 (2004) 652-655
24. Gonzalez-Gay M., and Garcia-Porrua C. Systemic vasculitis in adults in northwestern Spain, 1988-1997. Clinical and epidemiologic aspects. Medicine (Baltimore) 78 (1999) 292-308
25. Gonzalez-Gay M.A., Garcia-Porrua C., Amor-Dorado J.C., and Llorca J. Influence of age, sex, and place of residence on clinical expression of giant cell arteritis in northwest Spain. J Rheumatol 30 (2003) 1548-1551
26. Hayreh S.S., Zimmerman B., and Kardon R.H. Visual improvement with corticosteroid therapy in giant cell arteritis. Report of a large study and review of literature. Acta Ophthalmol Scand 80 (2002) 355-367
27. Aiello P.D., Trautmann J.C., McPhee T.J., Kunselman A.R., and Hunder G.G. Visual prognosis in giant cell arteritis. Ophthalmology 100 (1993) 550-555
28. Cid M.C., Font C., Oristrell J., de la Sierra A., Coll-Vinent B., Lopez-Soto A., et al. Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. Arthritis Rheum 41 (1998) 26-32
29. Liozon E., Herrmann F., Ly K., Robert P.Y., Loustaud V., Soria P., et al. Risk factors for visual loss in giant cell (temporal) arteritis: a prospective study of 174 patients. Am J Med 111 (2001) 211-217
30. Haugeberg G., Paulsen P.Q., and Bie R.B. Temporal arteritis in Vest Agder County in southern Norway: incidence and clinical findings. J Rheumatol 27 (2000) 2624-2627
31. Nesher G., Berkun Y., Mates M., Baras M., Nesher R., Rubinow A., et al. Risk factors for cranial ischemic complications in giant cell arteritis. Medicine (Baltimore) 83 (2004) 114-122
32. Hernandez-Rodriguez J., Segarra M., Vilardell C., Sanchez M., Garcia-Martinez A., Esteban M.J., et al. Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis: angiogenic activity of interleukin-6 as a potential protective mechanism. Circulation 107 (2003) 2428-2434
33. Cid M.C., Hernandez-Rodriguez J., Esteban M.J., Cebrian M., Gho Y.S., Font C., et al. Tissue and serum angiogenic activity is associated with low prevalence of ischemic complications in patients with giant-cell arteritis. Circulation 106 (2002) 1664-1671
34. Weyand C.M., Tetzlaff N., Bjornsson J., Brack A., Younge B., and Goronzy J.J. Disease patterns and tissue cytokine profiles in giant cell arteritis. Arthritis Rheum 40 (1997) 19-26
35. Weyand C.M., Ma-Krupa W., and Goronzy J.J. Immunopathways in giant cell arteritis and polymyalgia rheumatica. Autoimmun Rev 3 (2004) 46-53
36. Gonzalez-Gay M.A., Hajeer A.H., Dababneh A., Garcia-Porrua C., Amoli M.M., Llorca J., et al. Interferon-gamma gene microsatellite polymorphisms in patients with biopsy-proven giant cell arteritis and isolated polymyalgia rheumatica. Clin Exp Rheumatol 22 Suppl 36 (2004) S18-S20
37. Gonzalez-Gay M.A. Genetic epidemiology. Giant cell arteritis and polymyalgia rheumatica. Arthritis Res 3 (2001) 154-157
38. Gonzalez-Gay M.A., Amoli M.M., Garcia-Porrua C., and Ollier W.E. Genetic markers of disease susceptibility and severity in giant cell arteritis and polymyalgia rheumatica. Semin Arthritis Rheum 33 (2003) 38-48
39. Rueda B., Lopez-Nevot M.A., Lopez-Diaz M.J., Garcia-Porrua C., Martin J., and Gonzalez-Gay M.A. A functional variant of vascular endothelial growth factor is associated with severe ischemic complications in giant cell arteritis. J Rheumatol 32 (2005) 1737-1741
40. Lambrechts D., Storkebaum E., Morimoto M., Del-Favero J., Desmet F., Marklund S.L., et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 34 (2003) 383-394
41. Gonzalez-Gay M.A., Garcia-Porrua C., Llorca J., Gonzalez-Louzao C., and Rodriguez-Ledo P. Biopsy-negative giant cell arteritis: clinical spectrum and predictive factors for positive temporal artery biopsy. Semin Arthritis Rheum 30 (2001) 249-256